All Blogs

May 15, 2026

Summary NSCLC accounts for nearly 80–85% of all lung cancer cases. Among these patients, HER2 mutations are identified in roughly 1–4% of cases.  ENHERTU became the first FDA-approved therapy for unresectable/metastatic HER2 (ERBB2)-mutant NSCLC in 2022; however, along with recently approved HERNEXEOS and HY...

May 13, 2026

Cancer has long been called a silent killer, not because it lacks signs, but because those signs often arrive too late. For decades, oncology was dominated by a reactive model: patients presented with symptoms, received a diagnosis, and began treatment at an advanced stage when outcomes were already compromised. To...

May 12, 2026

GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China GSK plc revealed an exclusive strategic partnership with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aimed at supporting the launch and expansion of bepir...

May 11, 2026

Summary In the United States alone, agitation in Alzheimer’s disease represented nearly 5 million diagnosed cases, highlighting a considerable yet often underappreciated burden among patients. Brexpiprazole (REXULTI) marked a key milestone as the first FDA-approved therapy specifically indicated for agitatio...

May 08, 2026

Non-small Cell Lung Cancer (NSCLC) treatment has evolved from a chemotherapy-dominated approach to a biomarker-driven paradigm, enabled by the identification of multiple actionable alterations, including the EGFR signaling pathway, ALK, BRAF, RET, NTRK, HER2, KRAS, ROS1, and MET alterations. This shift has expanded...

May 07, 2026

Multi4 Medical Received CE Mark - Moves Bladder Cancer Treatment from Operating Room to Outpatient Setting On 05 May 2026, the CE mark enabled the Multi4 System to be commercialized across Europe and represented a major advancement in urologic cancer care. The system introduced the world’s first all-in-one instr...

May 06, 2026

Modern medicine is undergoing a profound shift toward procedures that reduce patient trauma while maintaining, or even improving, clinical outcomes. At the center of this transformation are minimally invasive surgical (MIS) devices, which enable surgeons to perform complex procedures through small incisions using a...

May 05, 2026

UCB Bets on Candid Therapeutics to Boost Immunology Pipeline with T-cell Engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics, strengthening its immunology pipeline and advancing its capabilities in next-generation biologics, particularly T-cell engagers (TCEs). The deal aligns wit...

May 04, 2026

The World Congress of Nephrology 2026 (WCN’26) is the flagship event of the International Society of Nephrology (ISN). The Congress was co-hosted by the Japanese Society of Nephrology (JSN) and the Asian Pacific Society of Nephrology (APSN). This conference marked a pivotal moment in the evolution of kidney disease...

May 01, 2026

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. The AACR Annual Meeting 2026 is one of the most prominent global oncology conferences, showcasing cutting-edge advances across cancer biology, translational research, and early ...